At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
00867 CMS
Trading 12-23 09:33:12
13.200
+0.030
+0.23%
High13.240Low13.060Vol27.00K
Open13.060D1 Closing13.170Amplitude1.37%
Mkt Cap32.21BTradable Cap32.20BTotal Shares2.44B
T/O355.80KT/O Rate0.00%Tradable Shares2.44B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
China Medical System Holdings (SEHK:867): Valuation Check After Y-3 Stroke Drug NDA Acceptance and Phase III Success
Simply Wall St.  ·  12-17
China Medical System Holdings (SEHK:867): Valuation Check After Y-3 Stroke Drug NDA Acceptance and Phase III Success
Guoyuan International Initiates "Buy" Rating on CMS (00867) with Target Price of HK$17.68
Stock News  ·  12-17
Guoyuan International Initiates "Buy" Rating on CMS (00867) with Target Price of HK$17.68
Dermavon Secures Breakthrough Drug Status for Oral JAK1 Inhibitor in China
Reuters  ·  12-15
Dermavon Secures Breakthrough Drug Status for Oral JAK1 Inhibitor in China
CMS (00867): Innovative Oral JAK1 Inhibitor Povorcitinib Included in Breakthrough Therapy List
Stock News  ·  12-15
CMS (00867): Innovative Oral JAK1 Inhibitor Povorcitinib Included in Breakthrough Therapy List
China Medical System's Povorcitinib Listed as Breakthrough Therapeutic Drug by China NMPA
Reuters  ·  12-15
China Medical System's Povorcitinib Listed as Breakthrough Therapeutic Drug by China NMPA
What China Medical System Holdings (SEHK:867)'s Stroke Drug NDA Acceptance Means For Shareholders
Simply Wall St.  ·  12-14
What China Medical System Holdings (SEHK:867)'s Stroke Drug NDA Acceptance Means For Shareholders
CMS (00867): China's NMPA Accepts New Drug Application for Class 1 Innovative Drug Y-3 Injection for Acute Ischemic Stroke
Stock News  ·  12-11
CMS (00867): China's NMPA Accepts New Drug Application for Class 1 Innovative Drug Y-3 Injection for Acute Ischemic Stroke
China Medical System - Nda of Class 1 Innovative Drug Y-3 for Injection Accepted by China's Nmpa
THOMSON REUTERS  ·  12-11
China Medical System - Nda of Class 1 Innovative Drug Y-3 for Injection Accepted by China's Nmpa
China Medical System's New Drug Application for Y-3 Injection Accepted in China
Reuters  ·  12-11
China Medical System's New Drug Application for Y-3 Injection Accepted in China
China Medical System Holdings (HKG:867) Could Easily Take On More Debt
Simply Wall St.  ·  12-10
China Medical System Holdings (HKG:867) Could Easily Take On More Debt
10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled
Stock News  ·  12-03
10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled
China Medical System (00867) Reports Unchanged Share Capital and Issued Shares for November 2025
Bulletin Express  ·  12-01
China Medical System (00867) Reports Unchanged Share Capital and Issued Shares for November 2025
China Medical System Holdings' (HKG:867) one-year total shareholder returns outpace the underlying earnings growth
Simply Wall St.  ·  11-22
China Medical System Holdings' (HKG:867) one-year total shareholder returns outpace the underlying earnings growth
Riding the Hong Kong Stock Rally: Bull Market Dawns in the East 2026 – 10th Zhitong Finance Capital Markets Annual Conference Invites You to a Capital Feast
Stock News  ·  11-18
Riding the Hong Kong Stock Rally: Bull Market Dawns in the East 2026 – 10th Zhitong Finance Capital Markets Annual Conference Invites You to a Capital Feast
Exclusive Novartis Ophthalmology Deal Might Change The Case For Investing In China Medical System Holdings (SEHK:867)
Simply Wall St.  ·  11-04
Exclusive Novartis Ophthalmology Deal Might Change The Case For Investing In China Medical System Holdings (SEHK:867)
Are China Medical System Holdings Limited's (HKG:867) Mixed Financials Driving The Negative Sentiment?
Simply Wall St.  ·  11-01
Are China Medical System Holdings Limited's (HKG:867) Mixed Financials Driving The Negative Sentiment?
China Medical System (00867) Issues Monthly Return for October 2025
Bulletin Express  ·  10-31
China Medical System (00867) Issues Monthly Return for October 2025
CMS (00867): China's NMPA Accepts Marketing Application for Long-Acting Anti-IL-4Rα Monoclonal Antibody for Atopic Dermatitis
Stock News  ·  10-30
CMS (00867): China's NMPA Accepts Marketing Application for Long-Acting Anti-IL-4Rα Monoclonal Antibody for Atopic Dermatitis
China Medical System Gets NMPA Acceptance for Atopic Dermatitis Drug Application
Reuters  ·  10-30
China Medical System Gets NMPA Acceptance for Atopic Dermatitis Drug Application
China Medical System - Nda for Atopic Dermatitis Indication of Long-Acting Anti-Il-4Ra Humanized Monoclonal Antibody Injection Accepted in China
THOMSON REUTERS  ·  10-30
China Medical System - Nda for Atopic Dermatitis Indication of Long-Acting Anti-Il-4Ra Humanized Monoclonal Antibody Injection Accepted in China

Introduction

Company Name.
CMS
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
China Medical System Holdings Ltd is an investment holding company principally engaged in the production of medicines, as well as marketing, promotion and sales of drugs. The Company's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The Company distributes its products within domestic market and to overseas markets.
Issue price:
--